Jeito Capital Secures $1.2 Billion for Second Biopharma Fund
European life sciences investor Jeito Capital has closed its second fund at $1.2 billion, creating what is being described as the largest independent biopharma-focused fundraise in Europe. The vehicle will back late-stage and growth opportunities in innovative biopharma companies, reinforcing Europe’s position in global healthcare innovation.
Focus on Transformative Biopharma and Late-Stage Growth
The new fund will target companies developing transformative therapies across areas such as oncology, rare diseases, immunology and advanced cell and gene therapies. By concentrating on late-stage and scaling businesses, Jeito Capital aims to accelerate the path from clinical development to commercialisation.
Unlike generalist venture capital funds, Jeito Capital operates with a specialist model, combining deep scientific expertise, regulatory know‑how and global commercial networks. This integrated approach is designed to help portfolio companies navigate complex clinical trials, market access hurdles and international expansion.
Signal of Strength for European Life Sciences
The $1.2 billion close is a strong vote of confidence in European life sciences at a time when many growth-stage technology and healthcare companies face tighter funding conditions. Institutional investors, including pension funds, sovereign wealth funds and insurance companies, are increasingly seeking exposure to resilient sectors such as biotech and biopharma.
Europe has long been a hub for scientific research, but historically many promising companies migrated to US capital markets. Large specialist funds like this one are intended to keep more value creation in the region by providing patient, scale-up capital within Europe.
Implications for Patients, Founders and the Ecosystem
For founders, the fund offers access to substantial follow‑on capital, enabling longer development runways and more ambitious clinical programmes. For patients, the expectation is faster development and broader availability of next‑generation treatments targeting high unmet medical needs.
The record-sized vehicle also underscores growing competition among specialist investors to lead European biopharma rounds. As more capital concentrates in expert hands, analysts expect increased scrutiny on scientific quality, robust regulatory strategies and clear commercial pathways for any company seeking backing from Jeito Capital and its peers.